SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person*

Lucidi Bruno

(Last) (First) (Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol

Atea Pharmaceuticals, Inc. [AVIR]

Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)

11/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

☑ Director ☐ 10% Owner

☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

☑ Form filed by One Reporting Person

☐ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/17/2026		M		21,628	A	$1.24	163,978	D	
Common Stock	11/17/2026		S		6,741	D	$4.0335(1)	157,237	D	
Common Stock	11/19/2026		M		53,372	A	$1.24	210,609	D	
Common Stock	11/19/2026		S		22,619	D	$3.9445(2)	187,990	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	$1.24	11/17/2026		M			21,628	(3)	12/08/2026	Common Stock	21,628	$0	53,372	D	
Stock Option (Right to Buy)	$1.24	11/19/2026		M			53,372	(3)	12/08/2026	Common Stock	53,372	$0	0	D	

Explanation of Responses:

1. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $3.97. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The option is fully vested and exercisable.

Remarks:

All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

/s/ Andrea Corcoran, as Attorney-in-Fact for Bruno Lucidi 11/19/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.